Chronic Obstructive Pulmonary Disease (COPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Chronic Obstructive Pulmonary Disease (COPD) is a significant global contributor to chronic illness and premature death. It afflicts many individuals for extended periods, ultimately leading to early mortality or related complications. As the fourth leading cause of death worldwide, COPD's prevalence and fatality rates are expected to rise in the coming decades. This condition initiates chronic inflammation, causing structural alterations and constriction in the smaller air passages. Inflammatory processes also contribute to lung tissue damage, resulting in the detachment of alveoli from the smaller airways and a decrease in lung elasticity, ultimately reducing the ability of airways to stay open during exhalation. To assess the extent of airflow restriction, spirometry serves as the most accessible and dependable measure of lung function. The impact of COPD on an individual patient is determined not only by the degree of airflow limitation but also by the severity of associated symptoms. An imperfect correlation exists between the degree of airflow limitation and symptoms. Consequently, spirometric staging is a practical approach intended for implementation, serving as an educational tool and offering a general indication for the initial management plan.

·       In the United States, COPD prevalence ranges from 6% to 11% among the adult population. The American Lung Association has reported that approximately 14 million American adults have received a COPD diagnosis. However, nearly 24 million American adults exhibit signs of impaired lung function, implying that COPD often goes undiagnosed.

 

Thelansis’s “Chronic Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Obstructive Pulmonary Disease (COPD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Chronic Obstructive Pulmonary Disease (COPD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Chronic Obstructive Pulmonary Disease (COPD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Chronic Obstructive Pulmonary Disease (COPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Chronic Obstructive Pulmonary Disease (COPD), Chronic Obstructive Pulmonary Disease (COPD) market outlook, Chronic Obstructive Pulmonary Disease (COPD) competitive landscape, Chronic Obstructive Pulmonary Disease (COPD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)